Abarceo Pharma

Executive Summary

Abarceo Pharma, a Swedish biotech spin-out from Lund University Diabetes Center, is pioneering a novel approach to treat diabetes by targeting the mitochondrial protein VDAC1 on beta cells. Founded in 2017 by renowned diabetes researchers Prof. Claes Wollheim and Assoc. Prof. Albert Salehi, the company aims to restore endogenous insulin production by reverting dysfunctional beta cells to a functional state. Their unique mechanism of action addresses a critical unmet need in diabetes care—preserving and potentially restoring beta cell function, offering an alternative to lifelong insulin therapy. Currently in the pre-clinical stage, Abarceo is focused on advancing its lead candidate toward clinical development. The company's innovative science, rooted in world-class research, positions it as a potential game-changer in diabetes treatment. With a clear therapeutic rationale and a strong scientific foundation, Abarceo is at an inflection point as it prepares for key milestones that will validate its platform and enable further investment.

Upcoming Catalysts (preview)

• Q2 2026Preclinical proof-of-concept data readout in animal models60% success
• Q4 2026IND-enabling studies initiation50% success
• TBDPartnership or licensing deal with a larger pharmaceutical company30% success